Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01383135 · ClinicalTrials.gov registry record · Early Phase 1
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT01383135: Completed Early Phase 1 study, sponsored by Stanford University.
NCT01383135 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01383135, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of the study was to conduct a pilot test of new tracers (\[18F\]FPRGD2 and \[18F\]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much stays in which organs and for how long), and radiation dosimetry (organ radiation dose). Healthy volunteers provided the normal biodistribution data. The same radiopharmaceutical was also tested in breast cancer, glioblastoma multiform (brain cancer), and lung cancer.
Interventions
- DRUG F18-FPPRGD2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01383135
The ClinicalTrials.gov registry entry for NCT01383135 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which F18-FPPRGD2 is the first listed.
NCT01383135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01383135 about?
NCT01383135 is a clinical study titled "Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2". The purpose of the study was to conduct a pilot test of new tracers (\[18F\]FPRGD2 and \[18F\]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much stays in which organs and for how long), and radiation dosimetry (organ...
What is the current status of trial NCT01383135?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2010-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01383135?
The interventions under investigation include: F18-FPPRGD2 (DRUG).
Who is sponsoring clinical trial NCT01383135?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.